Ami Fadia
Stock Analyst at Needham
(4.05)
# 573
Out of 4,996 analysts
390
Total ratings
46.61%
Success rate
13.88%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $30 → $28 | $21.05 | +33.02% | 11 | Sep 24, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $48 → $41 | $27.51 | +49.04% | 38 | Sep 24, 2025 | |
| BIIB Biogen | Reiterates: Hold | n/a | $137.37 | - | 43 | Sep 24, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $161 → $170 | $142.00 | +19.72% | 15 | Sep 22, 2025 | |
| IMRX Immuneering | Maintains: Buy | $8 → $11 | $8.08 | +36.14% | 19 | Sep 15, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $56 → $66 | $43.92 | +50.27% | 26 | Sep 11, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Buy | $202 | $127.00 | +59.06% | 34 | Aug 28, 2025 | |
| MRUS Merus | Maintains: Buy | $97 → $96 | $68.89 | +39.35% | 30 | Aug 6, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $18 → $16 | $6.77 | +136.34% | 21 | Aug 6, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Buy | $150 | $116.76 | +28.47% | 16 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $27.89 | +61.35% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $14.16 | - | 23 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $52.02 | +53.79% | 12 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $23.26 | +50.47% | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.74 | +187.36% | 9 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $15.34 | +23.86% | 36 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 | $7.40 | +292.16% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $320 | $16.00 | +1,900.00% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $25.24 | +197.15% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $23 | $0.72 | +3,025.43% | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $21.45 | +193.71% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $5 | $5.65 | -11.50% | 2 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $18.34 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.21 | +1,718.18% | 4 | Jan 3, 2018 |
ACADIA Pharmaceuticals
Sep 24, 2025
Maintains: Buy
Price Target: $30 → $28
Current: $21.05
Upside: +33.02%
Harmony Biosciences Holdings
Sep 24, 2025
Maintains: Buy
Price Target: $48 → $41
Current: $27.51
Upside: +49.04%
Biogen
Sep 24, 2025
Reiterates: Hold
Price Target: n/a
Current: $137.37
Upside: -
Neurocrine Biosciences
Sep 22, 2025
Maintains: Buy
Price Target: $161 → $170
Current: $142.00
Upside: +19.72%
Immuneering
Sep 15, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $8.08
Upside: +36.14%
Revolution Medicines
Sep 11, 2025
Maintains: Buy
Price Target: $56 → $66
Current: $43.92
Upside: +50.27%
Jazz Pharmaceuticals
Aug 28, 2025
Reiterates: Buy
Price Target: $202
Current: $127.00
Upside: +59.06%
Merus
Aug 6, 2025
Maintains: Buy
Price Target: $97 → $96
Current: $68.89
Upside: +39.35%
Day One Biopharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $18 → $16
Current: $6.77
Upside: +136.34%
Axsome Therapeutics
Aug 4, 2025
Reiterates: Buy
Price Target: $150
Current: $116.76
Upside: +28.47%
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $27.89
Upside: +61.35%
Jun 17, 2025
Reiterates: Hold
Price Target: n/a
Current: $14.16
Upside: -
Jun 12, 2025
Reiterates: Buy
Price Target: $80
Current: $52.02
Upside: +53.79%
May 28, 2025
Initiates: Buy
Price Target: $35
Current: $23.26
Upside: +50.47%
May 13, 2025
Reiterates: Buy
Price Target: $5
Current: $1.74
Upside: +187.36%
May 8, 2025
Reiterates: Buy
Price Target: $19
Current: $15.34
Upside: +23.86%
May 2, 2025
Reiterates: Buy
Price Target: $29
Current: $7.40
Upside: +292.16%
Feb 1, 2021
Maintains: Outperform
Price Target: $240 → $320
Current: $16.00
Upside: +1,900.00%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $25.24
Upside: +197.15%
Oct 1, 2020
Maintains: Market Perform
Price Target: $15 → $23
Current: $0.72
Upside: +3,025.43%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $21.45
Upside: +193.71%
Jan 30, 2019
Downgrades: Market Perform
Price Target: $12 → $5
Current: $5.65
Upside: -11.50%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $18.34
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $1.21
Upside: +1,718.18%